Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379893 | 0.79 | FTO (0.38) | LMNAGAA | |
| SCHEMBL5400629 | 0.78 | CA1 (0.36) | LMNA | |
| SCHEMBL5387264 | 0.78 | ATM (0.36) | LMNAGAAHTT | |
| SCHEMBL27522605 | 0.78 | — | — | |
| SCHEMBL15718171 | 0.74 | OXTR (0.33) | — | |
| SCHEMBL1600470 | 0.72 | HTR6 (0.46) | PTGS2 | |
| SCHEMBL5386852 | 0.69 | GLO1 (0.41) | LMNAPTGS1PTGS2ALOX15HTT | |
| SCHEMBL12813676 | 0.67 | — | — | |
| SCHEMBL16296752 | 0.66 | P4HTM (0.40) | LMNAPTGS1PTGS2ALOX15HTT | |
| SCHEMBL6643154 | 0.66 | PTGS2 (0.36) | TDP2NSD2ABL1PLCG1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | claimed |
| EP-2920163-B1 | PYRIDYLOXYAL ALKYL CARBOXAMIDES AND THEIR USE AS ENDOPARASITICIDES AND NEMATICIDE | BAYER CROPSCIENCE AG (DE) | 2018-05-02 | — | — | EP | claimed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| EP-2375898-B1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| EP-4023640-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
| CN-113200962-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-08-03 | — | — | CN | disclosed |
| CN-108430977-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-06-08 | — | — | CN | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| CN-1926127-A | Novel 2-heteroaryl substituted benzimidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-03-07 | — | — | CN | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| WO-2006066818-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066799-A1 | 7-AMINO-6-HETEROARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINES AND TO THE USE THEREOF FOR COMBATING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20050165020-A1 | 3-heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-1991006541-A1 | SULPHONATED HETEROCYCLIC CARBOXAMIDES AS HERBICIDES, GROWTH REGULATORS OR FUNGICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | LMNA 4373/4885TDP2 2857/4885NSD2 2588/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | LMNA 4383/4885TDP2 2440/4885NSD2 3303/4885 |
| US-20050165020-A1 | 3-heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides | CBR3, DDT, CYP4X1 | LMNA 4163/4885TDP2 2653/4885NSD2 2150/4885 |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | LMNA 1728/4885TDP2 757/4885NSD2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.